Investigating the optimum timeline for final cure assessment of treated Visceral Leishmaniasis patients in Bangladesh

Bangladesh became the first country globally to receive validation for the public health elimination of Visceral Leishmaniasis (VL). However, while VL cases have declined, sequels such as treatment failure and relapse are increasing. The current practice of assessing VL cure at six months post-treatment may delay the identification of sequelae. This study aims to determine the time required for VL patients to achieve complete clinical recovery and parasitological clearance, contributing to sustainable elimination efforts. We enrolled 50 confirmed VL patients from VL-endemic subdistricts of Mymensingh between June 2016 and March 2018. All the enrolled patients were treated with a single dose of Liposomal Amphotericin B (LAmB) (10 mg/kg intravenous infusion). Blood samples were collected upon admission and monthly for six months post-treatment. Polymerase chain reaction (PCR) was performed on these samples. The Kaplan-Meier method was used to estimate the cumulative probability of cure time, with clinical and laboratory parameters measured monthly. The median cure time for the participants was one month. Within three months, 90% of the patients were cured, and all patients fully recovered by six months. A significant difference in cure time was noted between individuals with spleen sizes below and above 8 cm (p = 0.0002). Additionally, nutritional improvements were evident, with increased BMI and a decrease in underweight proportions. Hemoglobin levels showed significant improvement in the early months post-treatment, with complete resolution or significant reduction of splenomegaly observed in all patients by three months, prompting reconsideration of the final cure declaration to three months instead of six months after treatment. Adjusting this cure declaration (while retaining 6, 12, 24, 36, 48, and 60 months of follow-up) will facilitate early detection of non-responsive cases and optimize resource allocation crucial for sustaining VL elimination efforts.

Authors

Institutions

Publication Details

Journal
PLOS Global Public Health
Published
2026-02-26
DOI
https://doi.org/10.1371/journal.pgph.0006002
Primary Topic
Research on Leishmaniasis Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Investigating the optimum timeline for final cure assessment of treated Visceral Leishmaniasis patients in Bangladesh

Soumik Kha Sagar, Shomik Maruf, Rajashree Chowdhury, Md. Masud Ur Rashid et al.
PLOS Global Public Health
Research on Leishmaniasis Studies
article

Investigating the optimum timeline for final cure assessment of treated Visceral Leishmaniasis patients in Bangladesh

Soumik Kha Sagar, Shomik Maruf, Rajashree Chowdhury, Md. Masud Ur Rashid, Rupen Nath, Faria Hossain, Debashis Ghosh, Md Utba Rashid, Prakash Ghosh, Sheikh Daud Adnan, Md Rasel Uddin, Dinesh Mondal, M. M. Aktaruzzaman, Md. Nazmul Islam
article en

Abstract

Bangladesh became the first country globally to receive validation for the public health elimination of Visceral Leishmaniasis (VL). However, while VL cases have declined, sequels such as treatment failure and relapse are increasing. The current practice of assessing VL cure at six months post-treatment may delay the identification of sequelae. This study aims to determine the time required for VL patients to achieve complete clinical recovery and parasitological clearance, contributing to sustainable elimination efforts. We enrolled 50 confirmed VL patients from VL-endemic subdistricts of Mymensingh between June 2016 and March 2018. All the enrolled patients were treated with a single dose of Liposomal Amphotericin B (LAmB) (10 mg/kg intravenous infusion). Blood samples were collected upon admission and monthly for six months post-treatment. Polymerase chain reaction (PCR) was performed on these samples. The Kaplan-Meier method was used to estimate the cumulative probability of cure time, with clinical and laboratory parameters measured monthly. The median cure time for the participants was one month. Within three months, 90% of the patients were cured, and all patients fully recovered by six months. A significant difference in cure time was noted between individuals with spleen sizes below and above 8 cm (p = 0.0002). Additionally, nutritional improvements were evident, with increased BMI and a decrease in underweight proportions. Hemoglobin levels showed significant improvement in the early months post-treatment, with complete resolution or significant reduction of splenomegaly observed in all patients by three months, prompting reconsideration of the final cure declaration to three months instead of six months after treatment. Adjusting this cure declaration (while retaining 6, 12, 24, 36, 48, and 60 months of follow-up) will facilitate early detection of non-responsive cases and optimize resource allocation crucial for sustaining VL elimination efforts.

PLOS Global Public HealthVol. 6(2)
Nebraska Medical Center (US), University of South Carolina (US), International Centre for Diarrhoeal Disease Research (BD), Institute of Empirical Health Economics (DE), Directorate General of Health Services (BD), National Heart Foundation Hospital & Research Institute (BD), University of Nebraska Medical Center (US), Leipzig University (DE)
Openalex Percentile: Top 46%
Research on Leishmaniasis Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.